Novel Pharmacotherapies in Parkinson’s Disease

被引:0
|
作者
Yousef Tizabi
Bruk Getachew
Michael Aschner
机构
[1] Howard University College of Medicine,Department of Pharmacology
[2] Department of Molecular Pharmacology,undefined
[3] Albert Einstein College of Medicine,undefined
来源
Neurotoxicity Research | 2021年 / 39卷
关键词
Parkinsonism; Nicotine; Butyrate; Short-chain fatty acids; Depression; Comorbidity; Combination therapy;
D O I
暂无
中图分类号
学科分类号
摘要
Parkinson’s disease (PD), an age-related progressive neurodegenerative condition, is associated with loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc), which results in motor deficits characterized by the following: akinesia, rigidity, resting tremor, and postural instability, as well as nonmotor symptoms such as emotional changes, particularly depression, cognitive impairment, gastrointestinal, and autonomic dysfunction. The most common treatment for PD is focused on dopamine (DA) replacement (e.g., levodopa = L-Dopa), which unfortunately losses its efficacy over months or years and can induce severe dyskinesia. Hence, more efficacious interventions without such adverse effects are urgently needed. In this review, following a general description of PD, potential novel therapeutic interventions for this devastating disease are examined. Specifically, the focus is on nicotine and nicotinic cholinergic system, as well as butyrate, a short chain fatty acid (SCFA), and fatty acid receptors.
引用
收藏
页码:1381 / 1390
页数:9
相关论文
共 50 条
  • [31] Novel Therapeutics for the Treatment of Alzheimer's and Parkinson's Disease
    Singh, Kavita
    Yadav, Dhananjay
    Chauhan, Pallavi S.
    Mishra, Meerambika
    Jin, Jun-O
    CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (07) : 755 - 763
  • [32] A novel treatment for Parkinson's disease using an immunomodulator
    Sredni, B
    Yadid, G
    Albeck, M
    Shalit, F
    Gefen, R
    JOURNAL OF NEUROCHEMISTRY, 2003, 85 : 90 - 90
  • [33] A role for a novel protein, nucleolin, in Parkinson's disease
    Caudle, W. Michael
    Kitsou, Efstathia
    Li, Jane
    Bradner, Joshua
    Zhang, Jing
    NEUROSCIENCE LETTERS, 2009, 459 (01) : 11 - 15
  • [34] Novel test for baroreceptor dysfunction in Parkinson's disease
    Christine Kyme
    Nature Clinical Practice Neurology, 2006, 2 (2): : 65 - 65
  • [35] Novel mitochondrial DNA mutations in Parkinson's disease
    G. Richter
    A. Sonnenschein
    T. Grünewald
    H. Reichmann
    B. Janetzky
    Journal of Neural Transmission, 2002, 109 : 721 - 729
  • [36] A novel formulation of selegiline for the treatment of Parkinson's disease
    Tetrud, JW
    Koller, WC
    NEUROLOGY, 2004, 63 (07) : S2 - S6
  • [37] A novel task to probe impulsivity in Parkinson's disease
    Adam, R.
    Bays, P. M.
    Singh-Curry, V.
    Bain, P.
    Husain, M.
    MOVEMENT DISORDERS, 2009, 24 : S289 - S289
  • [38] Novel neuroprotective agents for the treatment of Parkinson's disease
    George, J.
    Wilkins, S.
    Critch, N.
    Gunawan, L.
    Cortes, M.
    Liu, X.
    Laughton, K.
    Nurjono, M.
    Volitakis, I.
    Huggins, P.
    Parsons, J.
    McNaughton, M.
    Adlard, P.
    Masters, C.
    Cappai, R.
    Barnham, K.
    Gautier, E.
    Bush, A.
    Cherny, R.
    Finkelstein, D. I.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S41 - S42
  • [39] Parkinson's disease: The case for novel treatment strategies
    Stern, MB
    Freese, A
    EXPERIMENTAL NEUROLOGY, 1997, 144 (01) : 2 - 3
  • [40] A novel rehabilitation method for patients with Parkinson's disease
    Nagase, H.
    Aizawa, J.
    Hayashi, R.
    Ohara, S.
    MOVEMENT DISORDERS, 2006, 21 : S448 - S448